title: [Autologous peripheral blood stem cell transplantation in the treatment of patients with primary large mediastinal B-cell lymphoma].
abstract: OBJECTIVE
  To evaluate the therapeutic effectiveness and safety of high dose chemoradiotherapy (HDC) combined with autologous peripheral blood stem cell transplantation (APBSCT) in the treatment of patients with primary large mediastinal B-cell lymphoma (PMLBL).
  
  
  METHODS
  Among nine patients with PMLBL treated with APBSCT, high dose chemotherapy combined with total body irradiation (TBI) or total lymph node irradiation (TLI)/subtotal lymph node irradiation (STLI) were given to 7 patients and high dose chemotherapy only as pre-transplantation regimen in 2 patients. All patients received supplementary irradiation at the primary mediastinum after transplantation.
  
  
  RESULTS
  After a median follow-up of 24 (10 - 84) months, 5 patients achieved complete remission (CR) and 3 patients partial remission (PR) after induction chemotherapy. One patient developed progressive disease before transplantation. All 5 patients who achieved CR after induction chemotherapy became disease-free survivors (DFS). One of 3 patients who achieved PR after induction chemotherapy was DFS, the other two died in the third and fifth month, respectively. The patient who relapsed before transplantation died in the sixth month carrying the disease all along. According to the life table method, the cumulative probability of 7-year DFS and overall survival (OS) were both 66.7%. No transplant-related mortality was found.
  
  
  CONCLUSIONS
  High dose chemoradiotherapy combined with autologous peripheral blood stem cell transplantation is a highly potential therapeutic treatment for poor prognostic primary mediastinal large B-cell lymphoma.
authors.affiliation: Department of Medical Oncology, Cancer Institute (Hospital), Chinese Academy Medical Sciences, Peking Union Medical College, Beijing 100021, China.
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: He
authors.forename: Yuan-kai
authors.initials: YK
authors.lastname: Shi
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Han
authors.forename: Ai-ping
authors.initials: AP
authors.lastname: Zhou
authors.forename: Sheng-yu
authors.initials: SY
authors.lastname: Zhou
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Jian-liang
authors.initials: JL
authors.lastname: Yang
authors.forename: Feng-yi
authors.initials: FY
authors.lastname: Feng
mesh_terms: D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D016393:Lymphoma, B-Cell / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D014182:Transplantation, Autologous